Bevacizumab Combined with Continuation of EGFR-TKIs in NSCLC Beyond Gradual Progression

OBJECTIVE: Continuation of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) has shown potential in prolonging survival in patients with non-small cell lung cancer (NSCLC) harboring EGFR mutation who had gradual progression at initial targeting therapy. However, it remains un...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Ziyi, Teng, Fei, Hao, Xuezhi, Li, Junling, Xing, Puyuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9176636/
https://www.ncbi.nlm.nih.gov/pubmed/35693116
http://dx.doi.org/10.2147/CMAR.S363446

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9176636/
https://www.ncbi.nlm.nih.gov/pubmed/35693116
http://dx.doi.org/10.2147/CMAR.S363446

Ejemplares similares